Is it possible everything has been halted, essentially, for a buyout scenario? Aside from crunching the data on NASH, most clinical activity has been paused.

I say this bc I still found the abruptness of the call odd. Either they were purposely ducking investors bc they have little positive news to share, or they legally couldn’t talk about events in the offing.

Possible they could be waiting for resolution of audit in April.

On the flip side, the new hire would seem strange if that’s the case.